Clinical impact of probiotics on the efficacy of anti‐PD‐1 monotherapy in patients with nonsmall cell lung cancer: A multicenter retrospective survival analysis study with inverse probability of treatment weighting

The gastrointestinal microbiota was reported as an important factor for the response to cancer immunotherapy. Probiotics associated with gastrointestinal dysbiosis and bacterial richness may affect the efficacy of cancer immunotherapy drugs. However, the clinical impact of probiotics on the efficacy...

Full description

Saved in:
Bibliographic Details
Published in:International journal of cancer 2021-07, Vol.149 (2), p.473-482
Main Authors: Takada, Kazuki, Shimokawa, Mototsugu, Takamori, Shinkichi, Shimamatsu, Shinichiro, Hirai, Fumihiko, Tagawa, Tetsuzo, Okamoto, Tatsuro, Hamatake, Motoharu, Tsuchiya‐Kawano, Yuko, Otsubo, Kohei, Inoue, Koji, Yoneshima, Yasuto, Tanaka, Kentaro, Okamoto, Isamu, Nakanishi, Yoichi, Mori, Masaki
Format: Article
Language:English
Subjects:
Cancer
Cancer immunotherapy
Cell death
Disease control
Dysbacteriosis
Immunotherapy
Lung cancer
Medical research
Microbiota
Monoclonal antibodies
Nivolumab
Non-small cell lung carcinoma
nonsmall cell lung cancer
Patients
Pembrolizumab
Probiotics
prognostic factor
Survival analysis
Targeted cancer therapy
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The gastrointestinal microbiota was reported as an important factor for the response to cancer immunotherapy. Probiotics associated with gastrointestinal dysbiosis and bacterial richness may affect the efficacy of cancer immunotherapy drugs. However, the clinical impact of probiotics on the efficacy of cancer immunotherapy in patients with nonsmall cell lung cancer (NSCLC) is poorly understood. The outcomes of 294 patients with advanced or recurrent NSCLC who received antiprogrammed cell death‐1 (PD‐1) therapy (nivolumab or pembrolizumab monotherapy) at three medical centers in Japan were analyzed in our study. We used inverse probability of treatment weighting (IPTW) to minimize the bias arising from the patients' backgrounds. The IPTW‐adjusted Kaplan‐Meier curves showed that progression‐free survival (nonuse vs use: hazard ratio [HR] [95% confidence interval {CI}] = 1.73 [1.42‐2.11], log‐rank test P = .0229), but not overall survival (nonuse vs use: HR [95%CI] = 1.40 [1.13‐1.74], log‐rank test P = .1835), was significantly longer in patients who received probiotics. Moreover, the IPTW‐adjusted univariate analyses showed that nonuse or use of probiotics was significantly associated with disease control (nonuse vs use: odds ratio [OR] [95%CI] = 0.51 [0.35‐0.74], P = .0004) and overall response (nonuse vs use: OR [95%CI] = 0.43 [0.29‐0.63], P 
ISSN:0020-7136
1097-0215
DOI:10.1002/ijc.33557